Poteligeo Injection
Product Images NDC 42747-761

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Poteligeo (NDC 42747-761). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kyowa Kirin, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Poteligeo 01)

A Kaplan-Meier survival curve comparing progression-free survival percentages over time (months) between POTELIGEO and Vorinostat treatments. The chart displays a higher progression-free survival rate for POTELIGEO throughout the 36-month period, with the number of patients at risk shown below the x-axis for both groups at various time points.*

FDA Label Image

Principal Display Panel (4 mg/mL Vial Carton)

Packaging label for POTELIGEO (mogamulizumab-kpkc) injection, 20 mg/5 mL (4 mg/mL), for intravenous infusion. The label states it is a single-dose vial and unused portions should be discarded. Manufactured by Kyowa Kirin, Inc., Bedminster, NJ. Storage instructions include refrigeration at 2°C-8°C and protecting from light. Contains no preservatives.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.